Ovid Therapeutics/OVID

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Ovid Therapeutics

Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.

Ticker

OVID

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeremy Levin

Employees

40

Headquarters

New york, United States
Website
ovidrx.com

OVID Metrics

BasicAdvanced
$217M
Market cap
-
P/E ratio
-$0.72
EPS
0.58
Beta
-
Dividend rate
$217M
0.58035
$4.14
$2.57
189K
10.465
-36.86%
-50.87%
-39.08%
458.452
2.767
2.779
283.30%
1.72%
-68.57%

What the Analysts think about OVID

Analyst Ratings

Majority rating from 9 analysts.
Buy

OVID Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-11,600.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$100K
0.00%
Net income
-$12M
-24.18%
Profit margin
-11,600.00%
-24.18%

OVID Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.97%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.18
-$0.16
-$0.22
-$0.17
-
Expected
-$0.20
-$0.19
-$0.05
-$0.22
-$0.23
Surprise
-12.02%
-15.16%
342.53%
-21.97%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ovid Therapeutics stock?

Ovid Therapeutics (OVID) has a market cap of $217M as of June 19, 2024.

What is the P/E ratio for Ovid Therapeutics stock?

The price to earnings (P/E) ratio for Ovid Therapeutics (OVID) stock is 0 as of June 19, 2024.

Does Ovid Therapeutics stock pay dividends?

No, Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next Ovid Therapeutics dividend payment date?

Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders.

What is the beta indicator for Ovid Therapeutics?

Ovid Therapeutics (OVID) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Ovid Therapeutics stock price target?

The target price for Ovid Therapeutics (OVID) stock is $7.69, which is NaN% below the current price of $. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ovid Therapeutics stock

Buy or sell Ovid Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing